文献速递脑血管病

西洛他唑单药与联合治疗缺血性卒中:系统综述与荟萃分析更新

Cilostazol Mono and Combination Treatments in Ischemic Stroke: An Updated Systematic Review and Meta-Analysis.
PubMed 文献 · Stroke · 2019-10-14

结果显示西洛他唑单药及联合治疗均显著降低复发性卒中、缺血性卒中和复合结局风险,联合治疗在间接比较中更优,单药显著减少出血性卒中。

要点

  • 西洛他唑单药或联合治疗较SAPT显著降低复发性卒中和缺血性卒中风险。
  • 西洛他唑联合治疗在复发性卒中、缺血性卒中和复合结局上优于单药。
  • 西洛他唑单药显著减少出血性卒中,联合治疗不增加出血性卒中。

核心结论

  • 西洛他唑是比主要使用阿司匹林的SAPT更有效且更安全的治疗选择。
  • 西洛他唑联合治疗更有效降低复发性卒中和缺血性卒中,单药对出血性卒中更有益。

研究设计与样本

  • 系统综述与荟萃分析,检索MEDLINE、EMBASE和Cochrane数据库的随机对照试验。
  • 进行了网络荟萃分析以比较西洛他唑单药与联合治疗的相对效应。

主要发现

  • 西洛他唑单药及联合治疗复发性卒中、缺血性卒中和复合结局的相对风险显著低于SAPT,无异质性。
  • 间接比较显示西洛他唑联合治疗在复发性卒中、缺血性卒中和复合结局上优于单药。
  • 西洛他唑单药较SAPT显著减少出血性卒中,联合治疗较SAPT不增加出血性卒中。
  • 两种西洛他唑方案的心肌梗死结局与SAPT相当。

临床怎么用

  • 西洛他唑可作为缺血性卒中二级预防中替代主要使用阿司匹林的SAPT的方案。
  • 根据临床情况调整西洛他唑方案:联合治疗更有效降低复发性卒中和缺血性卒中,单药对出血性卒中更有益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background and Purpose- We performed a systematic review and meta-analysis to explore the efficacy and safety of cilostazol as a mono or combination (plus aspirin or clopidogrel) treatments compared to conventional single antiplatelet therapy (SAPT, mainly aspirin) for secondary stroke prevention. Methods- Randomized controlled trial studies were searched across multiple comprehensive databases (MEDLINE, EMBASE, and Cochrane) for review. The primary outcome was recurrent stroke comprising ischemic and hemorrhagic stroke. Secondary outcomes included ischemic stroke, hemorrhagic stroke, myocardial infarction, and composite outcomes. We performed an updated systematic review and meta-analysis of the identified reports, including 2 recently published randomized controlled trials. In addition, network meta-analysis was performed to compare the relative effects of mono versus combination cilostazol treatments. Results- Ten studies were included in this review, 5 of which were assigned to the cilostazol mono group (n=5429) and the other 5 to the combination group (n=2456). The relative risks of recurrent stroke, ischemic stroke, and composite outcomes with cilostazol mono as well as combination treatments were significantly lower than with SAPT without any significant heterogeneity. An indirect comparison of these 3 outcomes revealed the cilostazol combination approach to be superior. The cilostazol mono treatment diminished hemorrhagic stroke more significantly than SAPT and the cilostazol combination did not increase hemorrhagic stroke compared to SAPT. The outcomes from the 2 cilostazol regimens were comparable to SAPT in the case of myocardial infarction. Conclusions- Cilostazol is a more effective and safer treatment option than SAPT approaches using mainly aspirin. Cilostazol regimens can also be modified to clinical situations as this drug reduces recurrent and ischemic stroke more efficiently as a combination therapy but is more beneficial for hemorrhagic stroke as a monotherapy.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Kim SM, Jung JM, Kim BJ, et al. Cilostazol Mono and Combination Treatments in Ischemic Stroke: An Updated Systematic Review and Meta-Analysis. Stroke. 2019. PMID: 31607242. doi:10.1161/STROKEAHA.119.026655

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。